143 related articles for article (PubMed ID: 32696305)
1. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Preoperative Therapy for Resectable Gastric Adenocarcinoma: A Propensity Score-Matched Analysis of a Large, Single-Institution Experience.
Allen CJ; Blumenthaler AN; Smith GL; Das P; Minsky BD; Blum M; Ajani J; Mansfield PF; Ikoma N; Badgwell BD
Ann Surg Oncol; 2021 Feb; 28(2):758-765. PubMed ID: 32696305
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional Analysis.
Allen CJ; Pointer DT; Blumenthaler AN; Mehta RJ; Hoffe SE; Minsky BD; Smith GL; Blum M; Mansfield PF; Ikoma N; Das P; Ajani J; Dineen SP; Fleming JB; Badgwell BD; Pimiento JM
Ann Surg; 2021 Oct; 274(4):544-548. PubMed ID: 34132693
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant Chemotherapy vs Postoperative Observation Following Preoperative Chemoradiotherapy and Resection in Gastroesophageal Cancer: A Propensity Score-Matched Analysis.
Mokdad AA; Yopp AC; Polanco PM; Mansour JC; Reznik SI; Heitjan DF; Choti MA; Minter RR; Wang SC; Porembka MR
JAMA Oncol; 2018 Jan; 4(1):31-38. PubMed ID: 28975352
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma.
Mokdad AA; Minter RM; Yopp AC; Porembka MR; Wang SC; Zhu H; Augustine MM; Mansour JC; Choti MA; Polanco PM
J Natl Compr Canc Netw; 2018 Dec; 16(12):1468-1475. PubMed ID: 30545994
[No Abstract] [Full Text] [Related]
5. Neoadjuvant versus Postoperative Chemoradiotherapy is Associated with Improved Survival for Patients with Resectable Gastric and Gastroesophageal Cancer.
Kim DW; Lee G; Hong TS; Li G; Horick NK; Roeland E; Keane FK; Eyler C; Drapek LC; Ryan DP; Allen JN; Berger D; Parikh AR; Mullen JT; Klempner SJ; Clark JW; Wo JY
Ann Surg Oncol; 2022 Jan; 29(1):242-252. PubMed ID: 34480285
[TBL] [Abstract][Full Text] [Related]
6. Chemoradiation Improves Survival Compared With Chemotherapy Alone in Unresected Nonmetastatic Gastric Cancer.
Li R; Hou WH; Chao J; Woo Y; Glaser S; Amini A; Nelson RA; Chen YJ
J Natl Compr Canc Netw; 2018 Aug; 16(8):950-958. PubMed ID: 30099371
[No Abstract] [Full Text] [Related]
7. Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma: A National Cancer Data Base analysis.
Stumpf PK; Amini A; Jones BL; Koshy M; Sher DJ; Lieu CH; Schefter TE; Goodman KA; Rusthoven CG
Cancer; 2017 Sep; 123(17):3402-3409. PubMed ID: 28513823
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy versus chemoradiotherapy in the management of patients with surgically resected duodenal adenocarcinoma: A propensity score-matched analysis of a nationwide clinical oncology database.
Ecker BL; McMillan MT; Datta J; Lee MK; Karakousis GC; Vollmer CM; Drebin JA; Fraker DL; Roses RE
Cancer; 2017 May; 123(6):967-976. PubMed ID: 28263387
[TBL] [Abstract][Full Text] [Related]
9. Higher Doses of Neoadjuvant Radiation for Esophageal Cancer Do Not Affect the Pathologic Complete Response Rate or Survival: A Propensity-Matched Analysis.
Worrell SG; Towe CW; A Dorth J; Machtay M; Perry Y; Linden PA
Ann Surg Oncol; 2020 Feb; 27(2):500-508. PubMed ID: 31571054
[TBL] [Abstract][Full Text] [Related]
10. Total neoadjuvant therapy for pancreatic adenocarcinoma increases probability for a complete pathologic response.
Barrak D; Villano AM; Villafane-Ferriol N; Stockton LG; Hill MV; Deng M; Handorf EA; Reddy SS
Eur J Surg Oncol; 2022 Jun; 48(6):1356-1361. PubMed ID: 35016837
[TBL] [Abstract][Full Text] [Related]
11. Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base.
Rutter CE; Park HS; Corso CD; Lester-Coll NH; Mancini BR; Yeboa DN; Johung KL
Cancer; 2015 Dec; 121(23):4141-9. PubMed ID: 26280559
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
[TBL] [Abstract][Full Text] [Related]
13. Chemoradiotherapy versus chemotherapy as adjuvant treatment for localized gastric cancer: a propensity score-matched analysis.
Girardi DM; de Lima MA; Pereira GCB; Negrão MV; López RVM; Capareli FC; Sabbaga J; Hoff PMG
BMC Cancer; 2018 Apr; 18(1):378. PubMed ID: 29614980
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
Cats A; Jansen EPM; van Grieken NCT; Sikorska K; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; Boot H; Trip AK; Swellengrebel HAM; van Laarhoven HWM; Putter H; van Sandick JW; van Berge Henegouwen MI; Hartgrink HH; van Tinteren H; van de Velde CJH; Verheij M;
Lancet Oncol; 2018 May; 19(5):616-628. PubMed ID: 29650363
[TBL] [Abstract][Full Text] [Related]
15. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?
Papalezova KT; Tyler DS; Blazer DG; Clary BM; Czito BG; Hurwitz HI; Uronis HE; Pappas TN; Willett CG; White RR
J Surg Oncol; 2012 Jul; 106(1):111-8. PubMed ID: 22311829
[TBL] [Abstract][Full Text] [Related]
16. Does adjuvant chemoradiotherapy improve the prognosis of gastric cancer after an r1 resection? Results from a dutch cohort study.
Stiekema J; Trip AK; Jansen EP; Aarts MJ; Boot H; Cats A; Ponz OB; Gradowska PL; Verheij M; van Sandick JW
Ann Surg Oncol; 2015 Feb; 22(2):581-8. PubMed ID: 25164039
[TBL] [Abstract][Full Text] [Related]
17. No Survival Difference with Neoadjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base.
Al-Sukhni E; Gabriel E; Attwood K; Kukar M; Nurkin SJ; Hochwald SN
J Am Coll Surg; 2016 Dec; 223(6):784-792.e1. PubMed ID: 27641320
[TBL] [Abstract][Full Text] [Related]
18. Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States: A Propensity Score-matched Analysis.
Datta J; McMillan MT; Ecker BL; Karakousis GC; Mamtani R; Plastaras JP; Giantonio BJ; Drebin JA; Dempsey DT; Fraker DL; Roses RE
Ann Surg; 2016 Feb; 263(2):298-305. PubMed ID: 26135687
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score Adjusted Analysis.
Cloyd JM; Chen HC; Wang X; Tzeng CD; Kim MP; Aloia TA; Vauthey JN; Lee JE; Katz MHG
Pancreas; 2019 Feb; 48(2):216-222. PubMed ID: 30629022
[TBL] [Abstract][Full Text] [Related]
20. Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
Goense L; van der Sluis PC; van Rossum PSN; van der Horst S; Meijer GJ; Haj Mohammad N; van Vulpen M; Mook S; Ruurda JP; van Hillegersberg R
J Surg Oncol; 2017 Jun; 115(7):812-820. PubMed ID: 28267212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]